Impact of docetaxel plus ramucirumab in a second ‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

ConclusionOur retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.

Source: Thoracic Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Masaki Ishida, Kenji Morimoto, Tadaaki Yamada, Shinsuke Shiotsu, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Takeda, Koichi Takayama Tags: ORIGINAL ARTICLE Source Type: research